Lineage Cell Therapeutics Inc (LCTX) Stock Price, Quote & News

Company Profile

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the tre...

Industry: Biotechnology

Sector: Healthcare

Phone: 442 287 8990

Website: www.lineagecell.com

Address:

2173 Salk Avenue, Suite 200, Carlsbad, United States

MR_PINKS Feb. 24 at 8:55 PM

$LCTX Couple weeks away folks from abstract presentation/listings being made available! C-MAN you hear me?

0 · Reply

Wawawiiwa Feb. 24 at 8:19 PM

$LCTX we will be over 2$ soon enough!

1 · Reply

MR_PINKS Feb. 24 at 7:59 PM

$LCTX Stick the landing! $1.84

0 · Reply

Logic102 Feb. 24 at 7:47 PM

$LCTX Astellas is up 43% over the past 6 months and Lineage is up 51.6%. This sector has been en fuego.

1 · Reply

mktfixer Feb. 24 at 7:08 PM

$BRTX looks promising. Been following for long time stem cell is future $LCTX as well

1 · Reply

MR_PINKS Feb. 24 at 7:05 PM

$LCTX Dar, She...be!

0 · Reply

Logic102 Feb. 24 at 6:54 PM

$LCTX Interesting that Japan approved the allogenic IPS cell therapy treatment for Parkinson's disease with quite limited data. The US FDA has signalled it wants to be a leader in cell therapy and might consider quicker paths to approvals. Are we in a Cell Therapy race possibly?

2 · Reply

alphadog10 Feb. 24 at 6:53 PM

$LCTX I own more shares in this company than culley does. Does that make everyone feel more comfortable alpha dog with no insider knowledge owns more than the CEO who sees everything. Seems kind of concerning

1 · Reply

alphadog10 Feb. 24 at 6:48 PM

$LCTX Why doesnt culley ever buy any shares? Board should have selected better. They picked a broke divorced inbred eho cant even afford shares

0 · Reply

MNactuary Feb. 24 at 6:14 PM

$LCTX grabbed another 30k shares ... FOMO is a bitch.

1 · Reply

Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience

Jan 5, 2026, 8:00 AM EST - 7 weeks ago

Lineage Cell Therapeutics Issues Letter to Stockholders

Nov 13, 2025, 4:10 AM EST - 3 months ago

Lineage Cell Therapeutics: OpRegen Makes It A Viable Speculative Buy

Nov 6, 2025, 10:06 PM EST - 3 months ago

Lineage Cell Therapeutics, Inc. (LCTX) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:01 PM EST - 3 months ago

Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 30, 2025, 8:00 AM EDT - 4 months ago

Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Sep 13, 2025, 1:44 AM EDT - 5 months ago

Lineage Cell Therapeutics, Inc. (LCTX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Prepared Remarks Transcript

Sep 8, 2025, 8:00 AM EDT - 6 months ago

Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes

Sep 2, 2025, 8:00 AM EDT - 6 months ago

Lineage Cell Therapeutics to Present at September 2025 Investor Conferences

Aug 26, 2025, 8:00 AM EDT - 6 months ago

Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss

Aug 12, 2025, 9:16 PM EDT - 7 months ago

Lineage Cell Therapeutics, Inc. (LCTX) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:01 PM EDT - 7 months ago

Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 5, 2025, 8:00 AM EDT - 7 months ago

Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

Aug 4, 2025, 8:00 AM EDT - 7 months ago

Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury

Jun 23, 2025, 7:39 AM EDT - 8 months ago

Two Biotech Stocks Poised For Big Moves On Monday

SANA

Jun 23, 2025, 7:00 AM EDT - 8 months ago

OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025

Jun 5, 2025, 8:00 AM EDT - 9 months ago

Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium

May 14, 2025, 8:00 AM EDT - 10 months ago

Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

May 13, 2025, 5:53 PM EDT - 10 months ago

Lineage Cell Therapeutics, Inc. (LCTX) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:01 PM EDT - 10 months ago

Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 8:00 AM EDT - 10 months ago

RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025

May 1, 2025, 8:00 AM EDT - 10 months ago

Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

Apr 22, 2025, 8:00 AM EDT - 11 months ago

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium

Apr 21, 2025, 8:00 AM EDT - 11 months ago

Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)

Mar 10, 2025, 8:16 PM EDT - 1 year ago

Lineage Cell Therapeutics, Inc. (LCTX) Q4 2024 Earnings Call Transcript

Mar 10, 2025, 4:05 PM EDT - 1 year ago

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 5, 2025, 8:00 AM EST - 1 year ago

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025

Feb 11, 2025, 8:00 AM EST - 1 year ago

Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury

Feb 4, 2025, 8:00 AM EST - 1 year ago

Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference

Jan 27, 2025, 4:05 PM EST - 1 year ago

Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering

Nov 21, 2024, 5:00 PM EST - 1 year ago

Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering

Nov 20, 2024, 8:00 AM EST - 1 year ago

Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering

Nov 14, 2024, 9:39 PM EST - 1 year ago

Lineage Cell Therapeutics, Inc. (LCTX) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 4:01 PM EST - 1 year ago

Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 8:00 AM EST - 1 year ago

Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

Oct 14, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit

Sep 25, 2024, 8:00 AM EDT - 1 year ago

OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium

Sep 18, 2024, 8:00 AM EDT - 1 year ago

Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 10, 2024, 12:03 AM EDT - 1 year ago

Lineage Cell Therapeutics, Inc. (LCTX) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

Jul 2, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index

May 30, 2024, 8:00 AM EDT - 1 year ago

Lineage to Present at 2024 BIO International Convention

May 21, 2024, 8:00 AM EDT - 1 year ago

Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

May 10, 2024, 12:33 AM EDT - 1 year ago

Lineage Cell Therapeutics, Inc. (LCTX) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:01 PM EDT - 1 year ago

Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 6, 2024, 8:00 AM EDT - 1 year ago

OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

May 2, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Apr 30, 2024, 8:00 AM EDT - 1 year ago

Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)

MR_PINKS Feb. 24 at 8:55 PM

$LCTX Couple weeks away folks from abstract presentation/listings being made available! C-MAN you hear me?

0 · Reply

Wawawiiwa Feb. 24 at 8:19 PM

$LCTX we will be over 2$ soon enough!

1 · Reply

MR_PINKS Feb. 24 at 7:59 PM

$LCTX Stick the landing! $1.84

0 · Reply

Logic102 Feb. 24 at 7:47 PM

$LCTX Astellas is up 43% over the past 6 months and Lineage is up 51.6%. This sector has been en fuego.

1 · Reply

mktfixer Feb. 24 at 7:08 PM

$BRTX looks promising. Been following for long time stem cell is future $LCTX as well

1 · Reply

MR_PINKS Feb. 24 at 7:05 PM

$LCTX Dar, She...be!

0 · Reply

Logic102 Feb. 24 at 6:54 PM

2 · Reply

alphadog10 Feb. 24 at 6:53 PM

1 · Reply

alphadog10 Feb. 24 at 6:48 PM

$LCTX Why doesnt culley ever buy any shares? Board should have selected better. They picked a broke divorced inbred eho cant even afford shares

0 · Reply

MNactuary Feb. 24 at 6:14 PM

$LCTX grabbed another 30k shares ... FOMO is a bitch.

1 · Reply

MR_PINKS Feb. 24 at 6:14 PM

$LCTX Easy...easy, now!

1 · Reply

JohnPDaly Feb. 24 at 5:08 PM

Japan panel OK's 2 iPS cell therapies despite little data - The Niche $LCTX https://ipscell.com/2026/02/japan-panel-oks-2-ips-cell-therapies-despite-little-data/

0 · Reply

zacharyjay4934 Feb. 24 at 4:34 PM

$LCTX @alphadog10 the CEO explained it well in Q&A section of their Q3 call. They’re in frequent contact with Roche, who acquired proprietary surgical delivery devices for OpRegen in 2025. Roche is investing in OpRegen program (while cutting other pipeline assets) and opened more clinical sites for Galette study - Roche is just a bit secretive about progress. An update is expected soon from Roche / Genentech. It’s no secret everyone wants an update, and one is coming. Whether that’s through positive clinical data something larger, we will likely find out soon.

3 · Reply

alphadog10 Feb. 24 at 3:32 PM

$LCTX They are oblivious to the fact shareholders want returns here. According to JPM interview Culley swears up and down these old programs are ready to reach the bedside ! After decades. I dont believe it, everyone will be sitting here for 2 more years with no data if history is any indicator. Snake oil salesman

1 · Reply

alphadog10 Feb. 24 at 3:25 PM

$LCTX people in this one are begging for a 20 cent bump in share price while ignoring the fact capricor went from .88 in 2020 to $40 in 2025. Thats some real progress over 5 years. Cant do that here not with this idiot ceo and share count. Capricor share count is 51 million shares so obviously they are disciplined with how they manage their money and dont go after indications that take 3 decades to prove out (still with no market moving proof) get rid of these idiots running the company. The stock would trade at $10 tomorrow if they axed these clowns

1 · Reply

DiligentInvesting Feb. 24 at 2:43 PM

$LCTX Knocking at $1.8, me thinks it's gonna give. Check SLS and AVXL.

0 · Reply

MR_PINKS Feb. 24 at 2:34 PM

$LCTX We have to get that $1.84 close out of the way 1st! Let's go ladies it's C-MAN time.....

0 · Reply

Gromit00 Feb. 24 at 2:10 PM

$LCTX are we expecting to hear the go no go decision before the March 9th report?

1 · Reply

qwertylicious2003 Feb. 24 at 2:01 PM

$LCTX Interesting commentary from Poseida Executive chairman.

3 · Reply

Love_To_Learn Feb. 24 at 1:11 PM

$LCTX let us see what is done with u L ticker theme *

0 · Reply

DiligentInvesting Feb. 24 at 10:41 AM

$LCTX Just-in-time snapshot before the run to $4 😎

0 · Reply

JohnPDaly Feb. 24 at 1:54 AM

$LCTX https://x.com/nature/status/2025985759484719410?s=12

1 · Reply

Market Cap	407.68M
Revenue (ttm)	9.50M
Net Income (ttm)	-18.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-195.89%
Debt to Equity Ratio	0.00

Volume	617,500
Avg Vol	1,151,596
Day's Range	N/A - N/A
Shares Out	230.33M
Stochastic %K	83%
Beta	1.80
Analysts	Strong Sell
Price Target	$4.17